Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows promise in hematologic cancers but faces limitations like toxicity and efficacy, especially in solid tumors.
• Over 1,800 CAR T-cell clinical trials have been registered in the last decade, with 33% focusing on next-generation products by September 2025.

Purpose of the Study:

• To systematically review and classify multifunctional CAR T-cell approaches in clinical trials.
• To analyze the trends, diversity, and clinical outcomes of safety- and efficacy-enhancing strategies in CAR T-cell therapy.

Main Methods:

• Systematic review of CAR T-cell trials registered at ClinicalTrials.gov.
• Classification of multifunctional CAR T-cell trials into safety-enhancements and efficacy-enhancements.
• Monitoring registration frequency and analyzing available clinical results over twenty years.

Main Results:

• Efficacy enhancement strategies have progressed more rapidly in number and diversity than safety strategies.
• Multi-targeting approaches are increasingly prevalent in CAR T-cell trials.
• Emerging combined strategies aim to integrate both safety and efficacy enhancements.

Conclusions:

• Multifunctional CAR T-cell therapies represent a significant evolution in cancer treatment, addressing limitations of earlier generations.
• The field is rapidly advancing, with a clear trend towards more sophisticated CAR T-cell designs incorporating multiple functionalities.
• Future research will likely focus on optimizing combined safety and efficacy enhancements for broader clinical application.